Pharmacyclics Inc. (PCYC)
-NasdaqCM | Prev Close: | 82.35 |
|---|
| Open: | N/A |
|---|
| Bid: | 77.11 x 100 |
|---|
| Ask: | 90.00 x 1200 |
|---|
| 1y Target Est: | 98.91 |
|---|
| Beta: | 0.93 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 30.06 - 95.85 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 785,711 |
|---|
| Market Cap: | 5.99B |
|---|
| P/E (ttm): | 125.34 |
|---|
| EPS (ttm): | 0.66 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- FDA Designation for Synageva CandidateZacks(Wed, May 22)
- 2013 FDA Drug Approval Calendarat TheStreet(Tue, May 21)
- PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Tue, May 21)
- Tackling Cancer: Leukemia's Biggest Current and Upcoming Playersat Motley Fool(Sun, May 19)
- Wall Street Transcript Interview with Finny Kuruvilla, Portfolio Manager of the Eventide Gilead Fund: Investing in Health Care InnovationWall Street Transcript(Thu, May 16)
- PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Wed, May 15)
- With 'Cell Death' Drugs, Bristol-Myers May Win No Matter Whatat Forbes(Wed, May 15)
- ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Upat TheStreet(Wed, May 15)
- ASCO '13 Preview: Gilead's Big Cancer Debutat TheStreet(Wed, May 15)
- Three Value-Presenting Stocks With Upgrades on Mondayat Motley Fool(Wed, May 15)
- PHARMACYCLICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Submission of Matters to a Vote ofEDGAR Online(Tue, May 14)
- Pharmacyclics Rises On Unusually High Volume (PCYC)at TheStreet(Mon, May 13)
- 3 Biotech Stocks Spiking With Big Volumeat TheStreet(Mon, May 13)
- 6 Superstars For Your Biotech Portfolio: John McCamantat Seeking Alpha(Fri, May 10)
- Climbing the Wall of Worryat Motley Fool(Fri, May 10)
Comparison
| Symbol | % Chg | Mkt Cap |
|---|
| PCYC | 0.00% | 5.99B |
| NVO | 0.00% | 91.83B |
| TEVA | 0.00% | 33.53B |
| AGN | 0.00% | 28.97B |
| FRX | 0.00% | 9.99B |
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 36.19 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.90 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.04 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | -582.75 |
|---|
Business Summary
Pharmacyclics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of small-molecule drugs for the treatment of cancer and immune mediated diseases.
View More 
0.52%